Fluorescence Guided Surgery System Market

Fluorescence Guided Surgery System Market Outlook from 2024 to 2034

The fluorescence-guided surgery system market is predicted to increase from USD 110.8 million in 2024 to USD 468 million in 2034. Sales are projected to rise at a CAGR of 15.5% over the forecast period between 2024 and 2034.

The revenue generated by fluorescence-guided surgery system in 2023 was USD 92.7 million. The global fluorescence-guided surgery system industry is projected to rise due to increasing regulatory approvals, healthcare expenditure, and surging number of targeted surgical procedures.

Research and development have led to the improvement of fluorescence probes that are highly specific to cancerous cells or target tissues. These probes improve surgeons' visualization of the surgical site during procedures. Clinical data shows that fluorescence-guided surgery enhances patient outcomes, encouraging its adoption by healthcare institutions.

In April 2022, the Imperial Confidence in Concept grant was approved to produce fluorescence probes for tumor visualization during cancer surgery. As more instruments receive regulatory approval, fluorescence-guided surgery devices become increasingly accessible for clinical use.

By application, the fluorescence-guided surgery system market is segmented into cancer surgeries and cardiovascular surgeries, with cancer surgeries holding the leading share in 2023. Increasing incidence of cancer is projected to push demand for fluorescence-guided surgery systems in cancer treatment.

Fluorescence-guided surgery is set to enhance surgery accuracy and potentially improve patient outcomes. As per a report published by the National Institutes of Health (NIH), China witnessed an increase in cancer cases in 2023, with lung cancer being the most prevalent type.

The field of functional genomics (FGS) is undergoing significant developments due to progressions in imaging technology. These include high resolution, improved sensitivity, and real-time imaging, enabling surgeons to visualize target tissues more accurately.

The integration of FGS systems with surgical navigation platforms is becoming more common, providing real-time guidance and enhancing intraoperative decision-making. Leading manufacturers are also prioritizing patient safety and improving surgical outcomes by developing safe, biocompatible fluorescent agents.

Attributes	Description
Estimated Global Fluorescence Guided Surgery System Market Size (2024E)	USD 110.8 million
Projected Global Fluorescence Guided Surgery System Market Value (2034F)	USD 468 million
Value-based CAGR (2024 to 2034)	15.5%

Key Industry Highlights

Growing Need for Minimally Invasive Surgical Techniques to be a Key Trend

Growing demand for minimally invasive surgical techniques is fueling the adoption of FGS systems. These systems enable surgeons to accurately visualize target tissues, minimize damage to healthy tissue, and enhance patient outcomes in minimally invasive procedures.

Improved Surgical Outcomes Push Sales in the Industry

Increasing acceptance and adoption of FGS systems among healthcare providers is spurred by the growing clinical evidence supporting the efficacy. Clinical studies demonstrating improved surgical outcomes, reduced positive margin rates, and low recurrence rates are surging demand for FGS technology.

Stringent Regulatory Approval Process to Hinder Growth

Regulatory approvals for new fluorescent agents and imaging devices are set to be lengthy and complex, necessitating extensive preclinical and clinical testing. Delays are projected to hinder commercialization, limit market access, and slow market growth for manufacturers.

High Implementation and Maintenance Cost to Obstruct Demand

The high cost of fluorescence imaging systems and related equipment, including specialized devices, fluorescent agents, and surgical navigation software, is a significant restraining factor in the FGS system market. The implementation and maintenance of FGS systems are set to be costly for a few healthcare facilities, especially small clinics and resource-limited areas.

2019 to 2023 Global Fluorescence Guided Surgery System Sales Analysis Compared to Demand Forecast for 2024 to 2034

The global market recorded a CAGR of 20% during the historical period between 2019 and 2023. Fluorescence imaging, a surgical guidance technique, emerged between 2019 and 2023, using fluorescent dyes or contrast agents to differentiate between healthy and diseased tissue.

Over time, developments in imaging technologies have led to high-resolution images and enhanced tissue penetration, making fluorescence-guided surgery more accurate and reliable. Clinical validation and adoption have led to its acceptance in various surgical specialties, including oncology, neurosurgery, urology, and cardiovascular surgery.

FDA approvals have accelerated the commercialization and widespread adoption of fluorescence-guided surgery systems, allowing companies to offer integrated intraoperative visualization.

Fluorescence-guided surgery has extended into new clinical applications beyond oncology, including sentinel lymph node mapping, perfusion assessment, and organ preservation. Integration with surgical navigation systems has enhanced the accuracy and efficiency of fluorescence-guided procedures, providing real-time guidance.

The development of fluorescent agents is being pursued to improve the specificity of fluorescence-guided surgery. This is a result of binding the agents to specific molecular markers linked to diseases like cancer. By 2034, the industry is projected to reach USD 468 million.

Fluorescence-guided surgery necessitates specialized training and expertise among surgical teams. This encompasses fluorescence imaging techniques, signal interpretation, and integration into workflows. Increasing demand for resources and staff is projected to hinder the growth of healthcare institutions.

Comparative Market Overview

The section below compares two industries in the packaging division, namely, dental fluorescence analyzer and image-guided system industries. The information provided in the tables below would enable potential clients to make wise investment decisions and put efforts in the most beneficial zones.

Image Guided Radiotherapy Market:

The image guided radiotherapy market is broadening because of the increasing number of cancer cases worldwide and advancements in cancer treatments. Technology is getting better in the radiotherapy industry, and healthcare professionals are using different radiotherapy tools and methods. Individuals are learning more about how radiation therapy can help, which is helping the market to prosper further. Image-guided radiotherapy (IGRT) is popular because it can give better results, cause fewer side effects, and be more accurate.

Attributes	Description
Related Market	Image Guided Radiotherapy Market
CAGR (2024 to 2034)	14.7%
Growth Factor	Advancements in imaging technology, like MRI and CT scans, for accurate tumor localization
Opportunity	Development of compact and economical IGRT systems for smaller healthcare centers
Key Trend	Growing preference for adaptive radiotherapy for concurrent treatment adjustments based on patient anatomy

Image Guided System Industry Assessment:

Telemedicine and remote surgery are transforming healthcare by enabling surgeons to collaborate across geographical boundaries. This has led to the development of image-guided systems, which improve surgical precision, reduce complications, and optimize treatment efficacy.

Attributes	Description
Related Market	Image Guided System Industry
CAGR (2024 to 2034)	8.4%
Growth Factor	Hybrid operating rooms with innovative imaging and surgical navigation systems are gaining traction due to seamless transitions between imaging, planning, and surgical intervention.
Opportunity	Image-guided systems are increasingly used in minimally invasive procedures in neurosurgery, orthopedics, and interventional radiology, enhancing precision, reducing tissue trauma, and reducing patient recovery times.
Key Trend	AI and machine learning algorithms are being integrated into image-guided systems to improve image analysis, surgical planning, tumor detection, and real-time guidance during procedures.

Country-wise Insights

The following table shows the estimated growth rates of the leading markets. The United States is anticipated to remain at the forefront in North America, with a CAGR of 15.8% through 2034. In East Asia, Japan is projected to witness a CAGR of 17.4% by 2034, followed by China at 16.3%.

Countries	CAGR 2024 to 2034
United States	15.8%
United Kingdom	16.8%
China	16.3%
South Korea	18%
Japan	17.4%

Growing Prevalence of Chronic Diseases to Create Opportunities in the United Kingdom

The fluorescence-guided surgery system industry in the United Kingdom is projected to reach USD 18.9 million over the forecast period. The industry is projected to rise due to a huge patient population, presence of reputed manufacturers, high incidence of chronic diseases, and demand for novel surgical treatments.

Furthermore, rapidly developing healthcare expenditure, improving infrastructure, rising geriatric population, and high prevalence of lifestyle diseases are surging growth.

Technological Innovations in Healthcare to Fuel Sales in the United States

The United States is anticipated to record a CAGR of 15.8% during the evaluation period. The country is growing due to factors such as increasing cancer prevalence, launch of minimally invasive surgical techniques, and demand for precision-guided interventions.

The United States is a hub for technological innovation in healthcare, with companies investing heavily in research and development to advance fluorescence imaging technologies. Fluorescence-guided surgery has been widely adopted across various surgical specialties in the United States, including oncology, neurosurgery, urology, and cardiovascular surgery.

The United States Food and Drug Administration (FDA) plays a key role in regulating these systems and agents, ensuring safety and efficacy for clinical use. The market is highly competitive, with leading manufacturers and small companies vying for high shares.

Rising Clinical Research and Collaborations to Surge Demand in China

China is projected to showcase a CAGR of 16.3% in the forecast period. The country is a hub for clinical research and collaboration in fluorescence-guided surgery, involving academic institutions and healthcare providers in clinical trials and technology development.

Reimbursement policies and coverage for fluorescence-guided procedures vary depending on the specific application and healthcare provider. Efforts are ongoing to secure broad reimbursement coverage for fluorescence-guided procedures.

China is projected to continue growth and innovation with developments in imaging technology, targeted fluorescent agents, and surgical navigation systems.

Category-wise Insights

The section below analyzes the leading segment of the market. In terms of type, the SPY system segment accounted for a share of 34% in 2023. Based on surgery, the open surgery segment held a share of 65% in 2023.

High Efficiency and Easy Access to Make SPY Systems Popular

Segment	SPY System (Type)
Value Share (2023)	34%

The SPY system segment, which uses fluorescence-guided surgery (FGS) to improve surgical results, held the leading share in 2023 due to the increasing incidence of heart disorders.

FGS systems, like the SPY system, use real-time tissue perfusion monitoring and specific biological targets during surgery. The system enables surgeons to perform operations with few challenges and better patient outcomes.

Need for Precise Operations Creates High Demand for Open Surgeries

Segment	Open Surgery (Surgery)
Value Share (2023)	65%

The fluorescence-guided surgery system market is divided into open surgery and laparoscopy/endoscopy, with open surgery holding the leading share in 2023. This segment includes oncology, neurosurgery, cardiovascular, and gastrointestinal surgeries.

The industry is growing due to the need for efficient and precise operations. Fluorescence-guided surgery uses indocyanine green (ICG) to highlight specific tissues or structural components. This makes the open surgery a significant segment for those treatments not suitable with minimally invasive methods.

Competition Outlook

Stryker Corporation, Olympus Corporation, Medtronic PLC, OnLume Inc., and Getinge AB are key fluorescence-guided surgery system manufacturers listed in the report. The market evaluates leading companies in the industry based on product offerings, financial statements, key developments, strategic approach, position, and geographical penetration.

Strengths, weaknesses, opportunities, winning imperatives, current focus, strategies, and threats from competitors are also analyzed for key companies.

Several companies in the industry are focusing on partnerships, mergers and acquisitions, new product launches, and regional footprint extensions. Leading manufacturers of fluorescence-guided surgery systems are continuously refining existing products to meet evolving consumer expectations and demands.

Key manufacturers also employ strategies such as partnerships, distribution agreements, collaborations, advertisements, and celebrity endorsements to stay ahead of the competition. These strategies help several companies to enhance brand visibility, establish credibility, and gain a competitive advantage in the dynamic landscape.

Industry Updates

• In 2023, Unify Medical, headquartered in the United States, partnered with Mayo Clinic to develop medical devices using Unify's fluorescence-guided visualization technology.
• In 2024, Olympus Corporation, a Japan-based company, introduced the VISERA ELITE III Surgical Visualization Platform in Mexico. The platform is a fluorescence-guided surgical tool for healthcare professionals performing endoscopic procedures.
• In 2024, Leica Microsystems, headquartered in Germany, introduced an updated version of its ARveo 8 digital visualization microscope, which enhances surgical visualization in neurosurgery.

Leading Fluorescence Guided Surgery System Brands

• Stryker Corporation
• Hamamatsu Photonics K.K.
• Olympus Corporation
• Medtronic PLC
• OnLume Inc.
• Getinge AB
• Curadel LLC
• PerkinElmer, Inc.
• Karl Storz SE & Co. KG
• Irillic Pvt. Ltd
• Shimadzu Corporation

Key Segments of Market Report

By Type:

The industry is segregated into SPY system, PDE system, VS3 iridium system, and others.

By Surgery:

In terms of surgeries, the industry is divided into open surgery and laparoscopy/endoscopy.

By Application:

A few of the important applications include cancer surgeries, cardiovascular surgeries, and others.

By Region:

Key countries of North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa are covered.

Frequently Asked Questions

What is the future of fluorescence-guided surgery systems?

The industry is set to witness a CAGR of 15.5% by 2034.

What was the worth of the market from 2019 to 2023?

The industry witnessed a CAGR of 20% from 2019 to 2023.

How big is the fluorescence-guided surgery system industry?

In 2034, the industry is anticipated to reach USD 468 million.

Which country in Europe is set to lead the industry?

The United Kingdom is estimated to lead through 2034.

Who are the leading manufacturers?

Stryker Corporation, Olympus Corporation, Medtronic PLC.

Is there a market for fluorescence-guided surgery systems?

The market is set to reach USD 110.8 million by 2024.